… checkpoints remain unclear. By prospectively following a cohort of 292 patients with … immune
checkpoint inhibitors (ICIs), we identified 15 patients with acute or convalescent COVID-19 …

… immune checkpoint inhibitors (ICI) are at an increased risk of severe infection and mortality
during the corona … risk for SARS-CoV-2 infection as well as for a severe or fatal outcome of …

… mortality among cancer patients group treatment modalities such as immune therapy and …
of immune checkpoint inhibitors (ICIs) in cancer patients is safe during the COVID-19 pandemic…

… the immune checkpoint pathway and COVID-19 immunogenicity, ICIs therapy overactivated
T cells, which often leads to immune-related adverse events. In fact, the COVID-19 vaccine …

… From the start of the first epidemic wave of SARS-CoV-2 in Bergamo, Italy, we have
prospectively screened all consecutive outpatients who presented for treatment to the …

… immune protection against SARS-CoV-2 variants [17], we undertook a prospective study (NCT04743388)
in order to investigate the antibody responses after COVID-19 … immunological …

… of these two patients on the reciprocal interplay between ICI therapy and SARS-CoV-2 …
doable approach during the COVID-19 pandemic, and that SARS-CoV-2 infection does not seem …

… anti-CTLA-4 immune checkpoint inhibitors (ICI) currently used … , the patient undergoing
immune checkpoint blockade could be … COVID-19 pathogenesis & immune checkpoint blockade …

… responses against the virus. In the current review, we provide an overview of the potential
of checkpoint inhibitors to induce potent immune responses against SARS-CoV-2 and …

… for the kinetics of anti-SARS-CoV-2 antibodies after COVID-19 vaccination [4]. Herein, we …
) against SARS-CoV-2 in patients with solid tumors receiving immune checkpoint inhibitors (…